Polly Murphy is a seasoned pharmaceutical executive with extensive experience in business development, commercialization, and strategic planning. Currently serving as Chief Business Officer at Avadel Pharmaceuticals PLC and a board member at both Celcuity and Atea Pharmaceuticals, Polly previously held the position of Chief Business Officer at UroGen Pharma and held various leadership roles at Pfizer, including VP of Commercial Development and VP and Head of Strategy and Business Development in China. Polly's background also includes significant roles at The Scripps Research Institute and the Salk Institute, where responsibility encompassed licensing and commercialization. Polly holds a PhD in Veterinary Pathology from Iowa State University, an MBA from Nova Southeastern University, and a Doctor of Veterinary Medicine from Iowa State University.